{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:15:45Z","timestamp":1790014545517,"version":"4.0.1"},"reference-count":234,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,16]],"date-time":"2025-12-16T00:00:00Z","timestamp":1765843200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004387","name":"Ningbo University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004387","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007834","name":"Natural Science Foundation of Ningbo Municipality","doi-asserted-by":"publisher","award":["2024J342"],"award-info":[{"award-number":["2024J342"]}],"id":[{"id":"10.13039\/100007834","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008990","name":"Science and Technology Department of Zhejiang Province","doi-asserted-by":"publisher","award":["2025KY1317"],"award-info":[{"award-number":["2025KY1317"]}],"id":[{"id":"10.13039\/501100008990","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Genes &amp; Diseases"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.gendis.2025.101991","type":"journal-article","created":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T00:13:07Z","timestamp":1766189587000},"page":"101991","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Research progress in metabolic reprogramming and targeting metabolic pathways for clear cell renal cell carcinoma"],"prefix":"10.1016","volume":"13","author":[{"given":"Jia-tao","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-cheng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao-wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia-cheng","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke-jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sha-zhou","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang-yu","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai-chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5350-0362","authenticated-orcid":false,"given":"Qi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib1","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1093\/ndt\/gfae036","article-title":"Global epidemiology of kidney cancer","volume":"39","author":"Cirillo","year":"2024","journal-title":"Nephrol Dial Transplant"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib2","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.euf.2020.12.020","article-title":"A global trend analysis of kidney cancer incidence and mortality and their associations with smoking, alcohol consumption, and metabolic syndrome","volume":"8","author":"Huang","year":"2022","journal-title":"Eur Urol Focus"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib3","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1001\/jama.2024.12848","article-title":"Renal cell carcinoma: a review","volume":"332","author":"Rose","year":"2024","journal-title":"JAMA"},{"issue":"22","key":"10.1016\/j.gendis.2025.101991_bib4","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232214360","article-title":"Renal cell carcinoma as a metabolic disease: an update on main pathways, potential biomarkers, and therapeutic targets","volume":"23","author":"di Meo","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gendis.2025.101991_bib5","doi-asserted-by":"crossref","DOI":"10.1016\/j.mam.2024.101335","article-title":"The molecular code of kidney cancer: a path of discovery for gene mutation and precision therapy","volume":"101","author":"Xie","year":"2025","journal-title":"Mol Aspect Med"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib6","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.eururo.2025.09.4148","article-title":"Development and validation of a novel plasma metabolomic signature for the detection of renal cell carcinoma","volume":"89","author":"Huang","year":"2026","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib7","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s13402-023-00852-3","article-title":"Targeting ONECUT3 blocks glycolytic metabolism and potentiates anti-PD-1 therapy in pancreatic cancer","volume":"47","author":"Chen","year":"2024","journal-title":"Cell Oncol"},{"key":"10.1016\/j.gendis.2025.101991_bib8","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jare.2024.04.032","article-title":"MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma","volume":"70","author":"Wei","year":"2025","journal-title":"J Adv Res"},{"key":"10.1016\/j.gendis.2025.101991_bib9","doi-asserted-by":"crossref","first-page":"539","DOI":"10.34133\/research.0539","article-title":"STAT2\/SLC27A3\/PINK1-mediated mitophagy remodeling lipid metabolism contributes to pazopanib resistance in clear cell renal cell carcinoma","volume":"7","author":"Lu","year":"2024","journal-title":"Research"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib10","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1186\/s12943-024-02119-3","article-title":"Altered metabolism in cancer: insights into energy pathways and therapeutic targets","volume":"23","author":"Tufail","year":"2024","journal-title":"Mol Cancer"},{"issue":"15","key":"10.1016\/j.gendis.2025.101991_bib11","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.1016\/j.cell.2024.06.026","article-title":"100 years of the Warburg effect: a cancer metabolism endeavor","volume":"187","author":"Fendt","year":"2024","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41392-023-01362-2","article-title":"Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma","volume":"8","author":"Hu","year":"2023","journal-title":"Signal Transduct Target Ther"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib13","doi-asserted-by":"crossref","DOI":"10.1172\/JCI159839","article-title":"Hypoxia-inducible factors: cancer progression and clinical translation","volume":"132","author":"Wicks","year":"2022","journal-title":"J Clin Invest"},{"key":"10.1016\/j.gendis.2025.101991_bib14","first-page":"10017","article-title":"GLUT and HK: two primary and essential key players in tumor glycolysis","author":"Yadav","year":"2024","journal-title":"Semin Cancer Biol"},{"key":"10.1016\/j.gendis.2025.101991_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2023.102645","article-title":"Evolution of the HIF targeted therapy in clear cell renal cell carcinoma","volume":"121","author":"Golijanin","year":"2023","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib16","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1038\/s41581-023-00800-2","article-title":"Metabolic alterations in hereditary and sporadic renal cell carcinoma","volume":"20","author":"Coffey","year":"2024","journal-title":"Nat Rev Nephrol"},{"issue":"14","key":"10.1016\/j.gendis.2025.101991_bib17","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.4155\/fmc-2021-0071","article-title":"GLUT1 biological function and inhibition: research advances","volume":"13","author":"Cao","year":"2021","journal-title":"Future Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib18","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40001-024-01649-2","article-title":"Bioinformatics analysis identifies GLUD1 as a prognostic indicator for clear cell renal cell carcinoma","volume":"29","author":"Liu","year":"2024","journal-title":"Eur J Med Res"},{"key":"10.1016\/j.gendis.2025.101991_bib19","article-title":"Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential","volume":"15","author":"Sun","year":"2024","journal-title":"Front Pharmacol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib20","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.1111\/cas.16157","article-title":"Decreased risk of renal cell carcinoma in patients with type 2 diabetes treated with sodium glucose cotransporter-2 inhibitors","volume":"115","author":"Chiu","year":"2024","journal-title":"Cancer Sci"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib21","doi-asserted-by":"crossref","first-page":"946","DOI":"10.3390\/life13040946","article-title":"Aiding cancer\u2019s \u201csweet tooth\u201d: role of hexokinases in metabolic reprogramming","volume":"13","author":"Farooq","year":"2023","journal-title":"Life"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib22","article-title":"A pan-cancer analysis of the role of hexokinase II (HK2) in human tumors","volume":"12","author":"Li","year":"2022","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2025.101991_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.molmet.2018.11.013","article-title":"6-phosphofructo-2-kinase\/fructose-2, 6-biphosphatase 3 and 4: a pair of valves for fine-tuning of glucose metabolism in human cancer","volume":"20","author":"Yi","year":"2019","journal-title":"Mol Metab"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib24","doi-asserted-by":"crossref","first-page":"909","DOI":"10.3390\/cancers13040909","article-title":"Role of PFKFB3 and PFKFB4 in cancer: genetic basis, impact on disease development\/progression, and potential as therapeutic targets","volume":"13","author":"Kotowski","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib25","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12885-022-09183-2","article-title":"Overexpression of PFKFB3 promotes cell glycolysis and proliferation in renal cell carcinoma","volume":"22","author":"Li","year":"2022","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib26","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/s13046-021-02103-5","article-title":"PFKFB4 is overexpressed in clear-cell renal cell carcinoma promoting pentose phosphate pathway that mediates Sunitinib resistance","volume":"40","author":"Feng","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13105-024-01007-0","article-title":"The role of PKM2 in cancer progression and its structural and biological basis","volume":"80","author":"Wu","year":"2024","journal-title":"J Physiol Biochem"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib28","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.15252\/embr.201643300","article-title":"PKM2, cancer metabolism, and the road ahead","volume":"17","author":"Dayton","year":"2016","journal-title":"EMBO Rep"},{"issue":"9","key":"10.1016\/j.gendis.2025.101991_bib29","doi-asserted-by":"crossref","first-page":"8391","DOI":"10.3390\/ijms24098391","article-title":"PI3K\/AKT\/mTOR dysregulation and reprogramming metabolic pathways in renal cancer: crosstalk with the VHL\/HIF axis","volume":"24","author":"Badoiu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"44","key":"10.1016\/j.gendis.2025.101991_bib30","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000040273","article-title":"Central role of hypoxia-inducible factor-1\u03b1 in metabolic reprogramming of cancer cells: a review","volume":"103","author":"Zhu","year":"2024","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib31","doi-asserted-by":"crossref","first-page":"7339","DOI":"10.1038\/s41598-023-34087-x","article-title":"The expression pattern of pyruvate dehydrogenase kinases predicts prognosis and correlates with immune exhaustion in clear cell renal cell carcinoma","volume":"13","author":"Nunes-Xavier","year":"2023","journal-title":"Sci Rep"},{"issue":"Pt 2","key":"10.1016\/j.gendis.2025.101991_bib32","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.semcancer.2022.07.004","article-title":"\u2018Warburg effect\u2019 controls tumor growth, bacterial, viral infections and immunity - genetic deconstruction and therapeutic perspectives","volume":"86","author":"Pouyss\u00e9gur","year":"2022","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib33","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1186\/s12894-024-01580-y","article-title":"Advancements in research on lactate dehydrogenase A in urinary system tumors","volume":"24","author":"Zhuo","year":"2024","journal-title":"BMC Urol"},{"key":"10.1016\/j.gendis.2025.101991_bib34","article-title":"The novel role of LDHA\/LDHB in the prognostic value and tumor-immune infiltration in clear cell renal cell carcinoma","volume":"11","author":"Chen","year":"2023","journal-title":"PeerJ"},{"key":"10.1016\/j.gendis.2025.101991_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.semcancer.2023.01.007","article-title":"Targeting monocarboxylate transporters (MCTs) in cancer: how close are we to the clinics?","volume":"90","author":"Singh","year":"2023","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib36","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41392-024-02082-x","article-title":"Lactate and lactylation in cancer","volume":"10","author":"Chen","year":"2025","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib37","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1093\/carcin\/bgab100","article-title":"MCT1 expression is independently related to shorter cancer-specific survival in clear cell renal cell carcinoma","volume":"42","author":"de Carvalho","year":"2021","journal-title":"Carcinogenesis"},{"key":"10.1016\/j.gendis.2025.101991_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s12935-019-0889-8","article-title":"Monocarboxylate transporter 1 and monocarboxylate transporter 4 in cancer-endothelial co-culturing microenvironments promote proliferation, migration, and invasion of renal cancer cells","volume":"19","author":"Guo","year":"2019","journal-title":"Cancer Cell Int"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib39","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41585-022-00654-6","article-title":"Fatty acid metabolism reprogramming in ccRCC: mechanisms and potential targets","volume":"20","author":"Tan","year":"2023","journal-title":"Nat Rev Urol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101991_bib40","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/j.cmet.2021.08.012","article-title":"The thermogenic activity of adjacent adipocytes fuels the progression of ccRCC and compromises anti-tumor therapeutic efficacy","volume":"33","author":"Wei","year":"2021","journal-title":"Cell Metab"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153227","article-title":"Expression and prognostic significance of fatty acid synthase in clear cell renal cell carcinoma","volume":"216","author":"Yuan","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"15","key":"10.1016\/j.gendis.2025.101991_bib42","doi-asserted-by":"crossref","first-page":"3709","DOI":"10.1158\/0008-5472.CAN-11-4112","article-title":"ATP-citrate lyase: a key player in cancer metabolism","volume":"72","author":"Zaidi","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.gendis.2025.101991_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102056","article-title":"The prognostic value and its relationship with immune infiltration of ACLY in clear cell renal cell carcinoma","volume":"47","author":"Yin","year":"2024","journal-title":"Transl Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib44","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s10555-021-09996-w","article-title":"Lipid metabolism reprogramming in renal cell carcinoma","volume":"41","author":"Heravi","year":"2022","journal-title":"Cancer Metastasis Rev"},{"key":"10.1016\/j.gendis.2025.101991_bib45","article-title":"Acetyl-CoA carboxylases and diseases","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"issue":"26","key":"10.1016\/j.gendis.2025.101991_bib46","doi-asserted-by":"crossref","first-page":"6599","DOI":"10.7150\/jca.33024","article-title":"The mRNA expression signature and prognostic analysis of multiple fatty acid metabolic enzymes in clear cell renal cell carcinoma","volume":"10","author":"Zhao","year":"2019","journal-title":"J Cancer"},{"key":"10.1016\/j.gendis.2025.101991_bib47","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.canlet.2016.09.020","article-title":"Acetyl-CoA carboxylase rewires cancer metabolism to allow cancer cells to survive inhibition of the Warburg effect by cetuximab","volume":"384","author":"Luo","year":"2017","journal-title":"Cancer Lett"},{"key":"10.1016\/j.gendis.2025.101991_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-00793-4_1","article-title":"Fatty acid synthase: structure, function, and regulation","volume":"99","author":"G\u00fcnenc","year":"2022","journal-title":"Subcell Biochem"},{"key":"10.1016\/j.gendis.2025.101991_bib49","article-title":"Fatty acid synthase (FASN), a novel signature for visceral adipose tissues, regulates proliferation, migration and predicts prognosis of clear cell renal cell carcinoma","author":"Xu","year":"2020","journal-title":"Res Squa"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib50","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12672-024-01352-y","article-title":"AURKB affects the proliferation of clear cell renal cell carcinoma by regulating fatty acid metabolism","volume":"16","author":"Yang","year":"2025","journal-title":"Discov Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.trecan.2023.03.003","article-title":"Stearoyl coenzyme A desaturase-1: multitasker in cancer, metabolism, and ferroptosis","volume":"9","author":"Sen","year":"2023","journal-title":"Trends Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0166231","article-title":"High expression of stearoyl-CoA desaturase 1 predicts poor prognosis in patients with clear-cell renal cell carcinoma","volume":"11","author":"Wang","year":"2016","journal-title":"PLoS One"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib53","doi-asserted-by":"crossref","first-page":"9921","DOI":"10.3390\/ijms24129921","article-title":"Unveiling the MUFA-cancer connection: insights from endogenous and exogenous perspectives","volume":"24","author":"Guo","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"7","key":"10.1016\/j.gendis.2025.101991_bib54","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/s41568-022-00459-0","article-title":"Targeting ferroptosis as a vulnerability in cancer","volume":"22","author":"Lei","year":"2022","journal-title":"Nat Rev Cancer"},{"issue":"9","key":"10.1016\/j.gendis.2025.101991_bib55","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1158\/1078-0432.CCR-12-3249","article-title":"Stearoyl-CoA desaturase 1 is a novel molecular therapeutic target for clear cell renal cell carcinoma","volume":"19","author":"von Roemeling","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib56","doi-asserted-by":"crossref","first-page":"531","DOI":"10.3390\/molecules29020531","article-title":"CD36: the bridge between lipids and tumors","volume":"29","author":"Zhou","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.gendis.2025.101991_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.prostaglandins.2023.106732","article-title":"Comprehensive analysis of the roles of fatty acid transport related proteins in clear cell renal cell carcinoma","volume":"167","author":"Zheng","year":"2023","journal-title":"Prostaglandins Other Lipid Mediat"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2022.113389","article-title":"HIF-2\u03b1-induced upregulation of CD36 promotes the development of ccRCC","volume":"421","author":"Liao","year":"2022","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.gendis.2025.101991_bib59","article-title":"Identification of CPT1A as a prognostic biomarker and potential therapeutic target for kidney renal clear cell carcinoma and establishment of a risk signature of CPT1A-related genes","volume":"2020","author":"Xu","year":"2020","journal-title":"Int J Genom"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib60","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1038\/s41467-017-01965-8","article-title":"HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism","volume":"8","author":"Du","year":"2017","journal-title":"Nat Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib61","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/s12944-022-01726-7","article-title":"WY-14643 attenuates lipid deposition via activation of the PPAR\u03b1\/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC","volume":"21","author":"Wang","year":"2022","journal-title":"Lipids Health Dis"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib62","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3724\/abbs.2021023","article-title":"Overexpression CPT1A reduces lipid accumulation via PPAR\u03b1\/CD36 axis to suppress the cell proliferation in ccRCC","volume":"54","author":"Yang","year":"2022","journal-title":"Acta Biochim Biophys Sin"},{"issue":"3","key":"10.1016\/j.gendis.2025.101991_bib63","doi-asserted-by":"crossref","first-page":"C948","DOI":"10.1152\/ajpcell.00441.2023","article-title":"Ketone bodies in cell physiology and cancer","volume":"326","author":"Giuliani","year":"2024","journal-title":"Am J Physiol Cell Physiol"},{"issue":"22","key":"10.1016\/j.gendis.2025.101991_bib64","doi-asserted-by":"crossref","first-page":"4932","DOI":"10.3390\/nu14224932","article-title":"Molecular mechanisms for ketone body metabolism, signaling functions, and therapeutic potential in cancer","volume":"14","author":"Hwang","year":"2022","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib65","doi-asserted-by":"crossref","first-page":"210","DOI":"10.3390\/biomedicines13010210","article-title":"Comprehensive overview of ketone bodies in cancer metabolism: mechanisms and application","volume":"13","author":"Liang","year":"2025","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib66","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1007\/s11033-024-09355-2","article-title":"Improved therapy for clear cell renal cell carcinoma: beta-hydroxybutyrate and quercetin target hypoxia-induced angiogenesis and multidrug resistance","volume":"51","author":"Mohammadipoor","year":"2024","journal-title":"Mol Biol Rep"},{"key":"10.1016\/j.gendis.2025.101991_bib67","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2024.1344891","article-title":"Ketogenic diet enhances the anti-cancer effects of PD-L1 blockade in renal cell carcinoma","volume":"15","author":"Richard","year":"2024","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.gendis.2025.101991_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2021.153622","article-title":"Epigenetic inactivation of hydroxymethylglutaryl CoA synthase reduces ketogenesis and facilitates tumor cell motility in clear cell renal carcinoma","volume":"227","author":"Han","year":"2021","journal-title":"Pathol Res Pract"},{"key":"10.1016\/j.gendis.2025.101991_bib69","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.3389\/fonc.2019.01422","article-title":"Dysregulation of ketone body metabolism is associated with poor prognosis for clear cell renal cell carcinoma patients","volume":"9","author":"Cui","year":"2019","journal-title":"Front Oncol"},{"key":"10.1016\/j.gendis.2025.101991_bib70","doi-asserted-by":"crossref","DOI":"10.1016\/j.tranon.2024.102043","article-title":"ACAT1 suppresses clear cell renal cell carcinoma progression by AMPK mediated fatty acid metabolism","volume":"47","author":"Zheng","year":"2024","journal-title":"Transl Oncol"},{"key":"10.1016\/j.gendis.2025.101991_bib71","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2020.603837","article-title":"Metabolism of amino acids in cancer","volume":"8","author":"Wei","year":"2021","journal-title":"Front Cell Dev Biol"},{"issue":"7","key":"10.1016\/j.gendis.2025.101991_bib72","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2310479121","article-title":"Targeting MYC induces lipid droplet accumulation by upregulation of HILPDA in clear cell renal cell carcinoma","volume":"121","author":"Sainero-Alcolado","year":"2024","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"50","key":"10.1016\/j.gendis.2025.101991_bib73","doi-asserted-by":"crossref","first-page":"eabp8293","DOI":"10.1126\/sciadv.abp8293","article-title":"In vivo characterization of glutamine metabolism identifies therapeutic targets in clear cell renal cell carcinoma","volume":"8","author":"Kaushik","year":"2022","journal-title":"Sci Adv"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib74","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cmet.2019.11.020","article-title":"A variant of SLC1A5 is a mitochondrial glutamine transporter for metabolic reprogramming in cancer cells","volume":"31","author":"Yoo","year":"2020","journal-title":"Cell Metab"},{"key":"10.1016\/j.gendis.2025.101991_bib75","article-title":"High expression of solute carrier family 1, member 5 (SLC1A5) is associated with poor prognosis in clear-cell renal cell carcinoma","volume":"5","author":"Liu","year":"2015","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2025.101991_bib76","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.bbrc.2022.04.068","article-title":"Targeting of the glutamine transporter SLC1A5 induces cellular senescence in clear cell renal cell carcinoma","volume":"611","author":"Kawakami","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib77","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2290911","article-title":"Glutaminase inhibition as potential cancer therapeutics: current status and future applications","volume":"39","author":"Cyriac","year":"2024","journal-title":"J Enzym Inhib Med Chem"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib78","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1038\/nrc.2016.114","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat Rev Cancer"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib79","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0259241","article-title":"The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma","volume":"16","author":"Emberley","year":"2021","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib80","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1186\/s13062-024-00576-w","article-title":"Integrated machine learning reveals the role of tryptophan metabolism in clear cell renal cell carcinoma and its association with patient prognosis","volume":"19","author":"Li","year":"2024","journal-title":"Biol Direct"},{"issue":"18","key":"10.1016\/j.gendis.2025.101991_bib81","doi-asserted-by":"crossref","first-page":"18691","DOI":"10.1002\/cam4.6484","article-title":"The tryptophan-kynurenine pathway in immunomodulation and cancer metastasis","volume":"12","author":"Basson","year":"2023","journal-title":"Cancer Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib82","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12943-024-02164-y","article-title":"Molecular mechanisms and therapeutic significance of Tryptophan metabolism and signaling in cancer","volume":"23","author":"Yan","year":"2024","journal-title":"Mol Cancer"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib83","doi-asserted-by":"crossref","DOI":"10.1002\/cam4.70703","article-title":"The kynurenine pathway and indole pathway in tryptophan metabolism influence tumor progression","volume":"14","author":"Lu","year":"2025","journal-title":"Cancer Med"},{"key":"10.1016\/j.gendis.2025.101991_bib84","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2023.115804","article-title":"Interplay between estrogen, kynurenine, and AHR pathways: an immunosuppressive axis with therapeutic potential for breast cancer treatment","volume":"217","author":"Pacheco","year":"2023","journal-title":"Biochem Pharmacol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib85","doi-asserted-by":"crossref","first-page":"359","DOI":"10.3390\/cimb47050359","article-title":"Evaluation of the expression of IDO and PTEN in human kidney cancer","volume":"47","author":"K\u00f3nya","year":"2025","journal-title":"Curr Issues Mol Biol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101991_bib86","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1158\/0008-5472.CAN-23-2521","article-title":"PABPC1L induces IDO1 to promote tryptophan metabolism and immune suppression in renal cell carcinoma","volume":"84","author":"Shu","year":"2024","journal-title":"Cancer Res"},{"issue":"4_suppl","key":"10.1016\/j.gendis.2025.101991_bib87","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1200\/JCO.2024.42.4_suppl.452","article-title":"Association of microbial metabolism of tryptophan with resistance to immune checkpoint (ICB) therapy in renal cell cancer (RCC)","volume":"42","author":"Bari","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101991_bib88","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1111\/cas.14797","article-title":"Tryptophan 2, 3-dioxygenase in tumor cells is associated with resistance to immunotherapy in renal cell carcinoma","volume":"112","author":"Sumitomo","year":"2021","journal-title":"Cancer Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib89","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1186\/s12885-021-08477-1","article-title":"Clinicopathologic features of TDO2 overexpression in renal cell carcinoma","volume":"21","author":"Pham","year":"2021","journal-title":"BMC Cancer"},{"key":"10.1016\/j.gendis.2025.101991_bib90","doi-asserted-by":"crossref","DOI":"10.1177\/11786469231185102","article-title":"The role of the kynurenine\/AhR pathway in diseases related to metabolism and cancer","volume":"16","author":"Shadboorestan","year":"2023","journal-title":"Int J Tryptophan Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib91","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40170-023-00307-1","article-title":"Dual inhibition of IDO1\/TDO2 enhances anti-tumor immunity in platinum-resistant non-small cell lung cancer","volume":"11","author":"Wu","year":"2023","journal-title":"Cancer Metab"},{"issue":"10","key":"10.1016\/j.gendis.2025.101991_bib92","doi-asserted-by":"crossref","first-page":"2699","DOI":"10.1158\/2767-9764.CRC-24-0272","article-title":"Blocking tryptophan catabolism reduces triple-negative breast cancer invasive capacity","volume":"4","author":"Kuo","year":"2024","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.gendis.2025.101991_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114524","article-title":"Dual-target inhibitors of indoleamine 2, 3 dioxygenase 1 (Ido1): a promising direction in cancer immunotherapy","volume":"238","author":"Zhang","year":"2022","journal-title":"Eur J Med Chem"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib94","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.advms.2018.08.018","article-title":"Metabolic pathways of L-arginine and therapeutic consequences in tumors","volume":"64","author":"Szefel","year":"2019","journal-title":"Adv Med Sci"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib95","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41577-024-01098-2","article-title":"The roles of arginases and arginine in immunity","volume":"25","author":"Can\u00e8","year":"2025","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib96","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s40170-021-00271-8","article-title":"ASS1 and ASL suppress growth in clear cell renal cell carcinoma via altered nitrogen metabolism","volume":"9","author":"Khare","year":"2021","journal-title":"Cancer Metab"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib97","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1158\/1535-7163.MCT-12-0131","article-title":"A small-molecule inhibitor of glucose transporter 1 downregulates glycolysis, induces cell-cycle arrest, and inhibits cancer cell growth in vitro and in vivo","volume":"11","author":"Liu","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.gendis.2025.101991_bib98","first-page":"5","article-title":"Progression of bone-metastatic prostate cancer in a mouse model treated with a novel pan-class I GLUT inhibitor (DRB18)","volume":"11","author":"Hoggard","year":"2025","journal-title":"J Cancer Metastasis Treat"},{"issue":"94","key":"10.1016\/j.gendis.2025.101991_bib99","doi-asserted-by":"crossref","first-page":"94ra70","DOI":"10.1126\/scitranslmed.3002394","article-title":"Targeting GLUT1 and the Warburg effect in renal cell carcinoma by chemical synthetic lethality","volume":"3","author":"Chan","year":"2011","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib100","doi-asserted-by":"crossref","first-page":"6132","DOI":"10.1038\/s41598-020-63232-z","article-title":"Fasentin diminishes endothelial cell proliferation, differentiation and invasion in a glucose metabolism-independent manner","volume":"10","author":"Oca\u00f1a","year":"2020","journal-title":"Sci Rep"},{"key":"10.1016\/j.gendis.2025.101991_bib101","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.925666","article-title":"Glutor, a glucose transporter inhibitor, exerts antineoplastic action on tumor cells of thymic origin: implication of modulated metabolism, survival, oxidative stress, mitochondrial membrane potential, pH homeostasis, and chemosensitivity","volume":"12","author":"Temre","year":"2022","journal-title":"Front Oncol"},{"issue":"3","key":"10.1016\/j.gendis.2025.101991_bib102","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.chembiol.2021.10.007","article-title":"Inhibition of glucose transport synergizes with chemical or genetic disruption of mitochondrial metabolism and suppresses TCA cycle-deficient tumors","volume":"29","author":"Olszewski","year":"2022","journal-title":"Cell Chem Biol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101991_bib103","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/j.chembiol.2019.05.009","article-title":"Discovery of small-molecule selective mTORC1 inhibitors via direct inhibition of glucose transporters","volume":"26","author":"Kang","year":"2019","journal-title":"Cell Chem Biol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib104","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3892\/ol.2022.13521","article-title":"Dapagliflozin induces apoptosis by downregulating cFILPL and increasing cFILPS instability in Caki-1 cells","volume":"24","author":"Jang","year":"2022","journal-title":"Oncol Lett"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib105","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.3390\/ijms26125501","article-title":"Sodium-glucose cotransporter 2 and glucose levels affect clear cell renal cell carcinoma progression","volume":"26","author":"Nagata","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib106","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1038\/s42003-023-05289-w","article-title":"The SGLT2 inhibitor canagliflozin suppresses growth and enhances prostate cancer response to radiotherapy","volume":"6","author":"Ali","year":"2023","journal-title":"Commun Biol"},{"issue":"9","key":"10.1016\/j.gendis.2025.101991_bib107","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1007\/s00432-020-03278-8","article-title":"Targeting glycolysis with 2-deoxy-D-glucose sensitizes primary cell cultures of renal cell carcinoma to tyrosine kinase inhibitors","volume":"146","author":"Simon","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib108","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.3390\/biomedicines10051001","article-title":"Looking for the holy grail-drug candidates for glioblastoma multiforme chemotherapy","volume":"10","author":"Paj\u0105k","year":"2022","journal-title":"Biomedicines"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib109","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3390\/ijms21010234","article-title":"2-deoxy-d-glucose and its analogs: from diagnostic to therapeutic agents","volume":"21","author":"Pajak","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib110","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.545","article-title":"Primary clear cell renal carcinoma cells display minimal mitochondrial respiratory capacity resulting in pronounced sensitivity to glycolytic inhibition by 3-Bromopyruvate","volume":"6","author":"Nilsson","year":"2015","journal-title":"Cell Death Dis"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib111","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.3390\/cancers12113332","article-title":"The potential of lonidamine in combination with chemotherapy and physical therapy in cancer treatment","volume":"12","author":"Huang","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gendis.2025.101991_bib112","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2020.105367","article-title":"Novel selective hexokinase 2 inhibitor Benitrobenrazide blocks cancer cells growth by targeting glycolysis","volume":"164","author":"Zheng","year":"2021","journal-title":"Pharmacol Res"},{"issue":"9","key":"10.1016\/j.gendis.2025.101991_bib113","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.21037\/tcr-23-267","article-title":"The anti-tumor potential of sinomenine: a narrative review","volume":"12","author":"Zhu","year":"2023","journal-title":"Transl Cancer Res"},{"issue":"3","key":"10.1016\/j.gendis.2025.101991_bib114","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1096\/fj.201901237R","article-title":"Ikarugamycin inhibits pancreatic cancer cell glycolysis by targeting hexokinase 2","volume":"34","author":"Jiang","year":"2020","journal-title":"FASEB J"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib115","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1158\/1535-7163.MCT-07-0482","article-title":"Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth","volume":"7","author":"Clem","year":"2008","journal-title":"Mol Cancer Ther"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib116","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1158\/1535-7163.MCT-13-0097","article-title":"Targeting 6-phosphofructo-2-kinase (PFKFB3) as a therapeutic strategy against cancer","volume":"12","author":"Clem","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"15_suppl","key":"10.1016\/j.gendis.2025.101991_bib117","doi-asserted-by":"crossref","first-page":"TPS2606","DOI":"10.1200\/jco.2015.33.15_suppl.tps2606","article-title":"A phase I, dose-escalation, multi-center study of PFK-158 in patients with advanced solid malignancies explores a first-in-man inhbibitor of glycolysis","volume":"33","author":"Redman","year":"2015","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib118","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.3390\/cancers13051011","article-title":"Effects of the novel PFKFB3 inhibitor KAN0438757 on colorectal cancer cells and its systemic toxicity evaluation in vivo","volume":"13","author":"De Oliveira","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.gendis.2025.101991_bib119","doi-asserted-by":"crossref","first-page":"49","DOI":"10.3389\/fphar.2011.00049","article-title":"Anticancer targets in the glycolytic metabolism of tumors: a comprehensive review","volume":"2","author":"Porporato","year":"2011","journal-title":"Front Pharmacol"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib120","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.3390\/antiox10111831","article-title":"Shikonin induced program cell death through generation of reactive oxygen species in renal cancer cells","volume":"10","author":"Tsai","year":"2021","journal-title":"Antioxidants"},{"issue":"18","key":"10.1016\/j.gendis.2025.101991_bib121","doi-asserted-by":"crossref","first-page":"6725","DOI":"10.3390\/molecules28186725","article-title":"Shikonin causes an apoptotic effect on human kidney cancer cells through ras\/MAPK and PI3K\/AKT pathways","volume":"28","author":"Kir\u00e1ly","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib122","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/ijc.32756","article-title":"Benserazide is a novel inhibitor targeting PKM2 for melanoma treatment","volume":"147","author":"Zhou","year":"2020","journal-title":"Int J Cancer"},{"issue":"23","key":"10.1016\/j.gendis.2025.101991_bib123","doi-asserted-by":"crossref","first-page":"17304","DOI":"10.1021\/acs.jmedchem.1c01380","article-title":"Parthenolide derivatives as PKM2 activators showing potential in colorectal cancer","volume":"64","author":"Liu","year":"2021","journal-title":"J Med Chem"},{"key":"10.1016\/j.gendis.2025.101991_bib124","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/8201079","article-title":"Dichloroacetate (DCA) and cancer: an overview towards clinical applications","volume":"2019","author":"Tataranni","year":"2019","journal-title":"Oxid Med Cell Longev"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib125","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3390\/biomedicines8050119","article-title":"Discovery of hordenine as a potential inhibitor of pyruvate dehydrogenase kinase 3: implication in lung cancer therapy","volume":"8","author":"Anwar","year":"2020","journal-title":"Biomedicines"},{"key":"10.1016\/j.gendis.2025.101991_bib126","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.bbrc.2021.11.102","article-title":"A novel PDK1 inhibitor, JX06, inhibits glycolysis and induces apoptosis in multiple myeloma cells","volume":"587","author":"Kawano","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib127","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188559","article-title":"Metabolic reprogramming in renal cancer: events of a metabolic disease","volume":"1876","author":"Chakraborty","year":"2021","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib128","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/ptr.6587","article-title":"Plant-derived glucose transport inhibitors with potential antitumor activity","volume":"34","author":"Shriwas","year":"2020","journal-title":"Phytother Res"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib129","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1038\/s41467-022-30326-3","article-title":"Molecular basis for inhibiting human glucose transporters by exofacial inhibitors","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"issue":"41","key":"10.1016\/j.gendis.2025.101991_bib130","doi-asserted-by":"crossref","first-page":"8834","DOI":"10.1021\/bi200748b","article-title":"Hexose transporter GLUT1 harbors several distinct regulatory binding sites for flavones and tyrphostins","volume":"50","author":"P\u00e9rez","year":"2011","journal-title":"Biochemistry"},{"key":"10.1016\/j.gendis.2025.101991_bib131","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.738961","article-title":"Counteracting action of curcumin on high glucose-induced chemoresistance in hepatic carcinoma cells","volume":"11","author":"Soni","year":"2021","journal-title":"Front Oncol"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib132","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.3390\/nu14112274","article-title":"Therapeutic potential of natural products in the treatment of renal cell carcinoma: a review","volume":"14","author":"Feng","year":"2022","journal-title":"Nutrients"},{"key":"10.1016\/j.gendis.2025.101991_bib133","doi-asserted-by":"crossref","first-page":"4","DOI":"10.3389\/fmolb.2020.00004","article-title":"Molecular dynamics simulations of a chimeric androgen receptor protein (SPARKI) confirm the importance of the dimerization domain on DNA binding specificity","volume":"7","author":"Bagherpoor Helabad","year":"2020","journal-title":"Front Mol Biosci"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib134","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1007\/s11255-019-02372-2","article-title":"Genistein inhibited the proliferation of kidney cancer cells via CDKN2a hypomethylation: role of abnormal apoptosis","volume":"52","author":"Ji","year":"2020","journal-title":"Int Urol Nephrol"},{"issue":"10","key":"10.1016\/j.gendis.2025.101991_bib135","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1038\/bjc.2013.173","article-title":"Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in renal cancer cells","volume":"108","author":"Hirata","year":"2013","journal-title":"Br J Cancer"},{"issue":"23","key":"10.1016\/j.gendis.2025.101991_bib136","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.3390\/cancers14235811","article-title":"SGLT-2 inhibitors in cancer treatment-mechanisms of action and emerging new perspectives","volume":"14","author":"Dutka","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib137","doi-asserted-by":"crossref","first-page":"9711","DOI":"10.1021\/acsnano.0c01350","article-title":"3-bromopyruvate-conjugated nanoplatform-induced pro-death autophagy for enhanced photodynamic therapy against hypoxic tumor","volume":"14","author":"Deng","year":"2020","journal-title":"ACS Nano"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib138","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12951-023-01970-8","article-title":"3-Bromopyruvate-loaded bismuth sulfide nanospheres improve cancer treatment by synergizing radiotherapy with modulation of tumor metabolism","volume":"21","author":"He","year":"2023","journal-title":"J Nanobiotechnol"},{"issue":"18","key":"10.1016\/j.gendis.2025.101991_bib139","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1021\/acs.nanolett.1c03089","article-title":"GSH-responsive nanoprodrug to inhibit glycolysis and alleviate immunosuppression for cancer therapy","volume":"21","author":"Liu","year":"2021","journal-title":"Nano Lett"},{"issue":"14","key":"10.1016\/j.gendis.2025.101991_bib140","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1039\/D2BM00650B","article-title":"Nanodrug regulates lactic acid metabolism to reprogram the immunosuppressive tumor microenvironment for enhanced cancer immunotherapy","volume":"10","author":"Tian","year":"2022","journal-title":"Biomater Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib141","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s12951-022-01761-7","article-title":"Nanomedicine for renal cell carcinoma: imaging, treatment and beyond","volume":"21","author":"Wu","year":"2023","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.gendis.2025.101991_bib142","article-title":"PFKFB3 regulates chemoresistance, metastasis and stemness via IAP proteins and the NF-\u03baB signaling pathway in ovarian cancer","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"issue":"18","key":"10.1016\/j.gendis.2025.101991_bib143","doi-asserted-by":"crossref","first-page":"3067","DOI":"10.1002\/1873-3468.13878","article-title":"Small molecule 3PO inhibits glycolysis but does not bind to 6-phosphofructo-2-kinase\/fructose-2, 6-bisphosphatase-3 (PFKFB3)","volume":"594","author":"Emini","year":"2020","journal-title":"FEBS Lett"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib144","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10555-022-10027-5","article-title":"Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux","volume":"41","author":"Jones","year":"2022","journal-title":"Cancer Metastasis Rev"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib145","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40164-022-00303-z","article-title":"Metabolic cross-talk within the bone marrow milieu: focus on multiple myeloma","volume":"11","author":"Oudaert","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib146","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.3390\/cancers14051114","article-title":"Shikonin inhibits cell growth of sunitinib-resistant renal cell carcinoma by activating the necrosome complex and inhibiting the AKT\/mTOR signaling pathway","volume":"14","author":"Markowitsch","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib147","doi-asserted-by":"crossref","first-page":"265","DOI":"10.3390\/cancers15010265","article-title":"Novel specific pyruvate kinase M2 inhibitor, compound 3h, induces apoptosis and autophagy through suppressing Akt\/mTOR signaling pathway in LNCaP cells","volume":"15","author":"Jiang","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib148","doi-asserted-by":"crossref","first-page":"144","DOI":"10.3892\/ijo.2022.5434","article-title":"TRIM35 ubiquitination regulates the expression of PKM2 tetramer and dimer and affects the malignant behaviour of breast cancer by regulating the Warburg effect","volume":"61","author":"Wu","year":"2022","journal-title":"Int J Oncol"},{"issue":"20","key":"10.1016\/j.gendis.2025.101991_bib149","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.2174\/0929867331666230714144851","article-title":"Recent advances on PKM2 inhibitors and activators in cancer applications","volume":"31","author":"Chen","year":"2024","journal-title":"Curr Med Chem"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib150","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3390\/ph17060744","article-title":"Dichloroacetate for cancer treatment: some facts and many doubts","volume":"17","author":"Koltai","year":"2024","journal-title":"Pharmaceuticals"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib151","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/bjc.2012.559","article-title":"Activating oxidative phosphorylation by a pyruvate dehydrogenase kinase inhibitor overcomes sorafenib resistance of hepatocellular carcinoma","volume":"108","author":"Shen","year":"2013","journal-title":"Br J Cancer"},{"issue":"21","key":"10.1016\/j.gendis.2025.101991_bib152","doi-asserted-by":"crossref","first-page":"14683","DOI":"10.1021\/acs.jmedchem.3c01197","article-title":"Reprogramming energy metabolism with synthesized PDK inhibitors based on dichloroacetate derivatives and targeted delivery systems for enhanced cancer therapy","volume":"66","author":"She","year":"2023","journal-title":"J Med Chem"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib153","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20204402","article-title":"Pyruvate dehydrogenase kinases (PDKs): an overview toward clinical applications","volume":"41","author":"Wang","year":"2021","journal-title":"Biosci Rep"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib154","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/s41420-025-02479-9","article-title":"The pathogenesis and therapeutic implications of metabolic reprogramming in renal cell carcinoma","volume":"11","author":"Zhang","year":"2025","journal-title":"Cell Death Discov"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s40164-025-00622-x","article-title":"Lactylation modification in cancer: mechanisms, functions, and therapeutic strategies","volume":"14","author":"Lv","year":"2025","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib156","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1080\/15548627.2023.2249762","article-title":"Tumor-derived lactate promotes resistance to bevacizumab treatment by facilitating autophagy enhancer protein RUBCNL expression through histone H3 lysine 18 lactylation (H3K18la) in colorectal cancer","volume":"20","author":"Li","year":"2024","journal-title":"Autophagy"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib157","doi-asserted-by":"crossref","first-page":"2037","DOI":"10.1073\/pnas.0914433107","article-title":"Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression","volume":"107","author":"Le","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"14","key":"10.1016\/j.gendis.2025.101991_bib158","doi-asserted-by":"crossref","first-page":"3146","DOI":"10.3390\/molecules25143146","article-title":"Potential therapeutic targets of epigallocatechin gallate (EGCG), the most abundant catechin in green tea, and its role in the therapy of various types of cancer","volume":"25","author":"Almatroodi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.gendis.2025.101991_bib159","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.752118","article-title":"Galloflavin relieves the malignant behavior of colorectal cancer cells in the inflammatory tumor microenvironment","volume":"12","author":"Guo","year":"2021","journal-title":"Front Pharmacol"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib160","doi-asserted-by":"crossref","first-page":"5710","DOI":"10.3390\/ijms26125710","article-title":"Oxamate, an LDHA inhibitor, inhibits stemness, including EMT and high DNA repair ability, induces senescence, and exhibits radiosensitizing effects in glioblastoma cells","volume":"26","author":"Hashimoto","year":"2025","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.gendis.2025.101991_bib161","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1349745","article-title":"A comprehensive evaluation of the therapeutic potential of silibinin: a ray of hope in cancer treatment","volume":"15","author":"Ray","year":"2024","journal-title":"Front Pharmacol"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib162","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/path.6066","article-title":"Metformin confers sensitisation to syrosingopine in multiple myeloma cells by metabolic blockage and inhibition of protein synthesis","volume":"260","author":"Van der Vreken","year":"2023","journal-title":"J Pathol"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib163","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1158\/1078-0432.CCR-22-2263","article-title":"A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer","volume":"29","author":"Halford","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib164","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11596-020-2165-5","article-title":"Natural products and derivatives targeting at cancer energy metabolism: a potential treatment strategy","volume":"40","author":"Wang","year":"2020","journal-title":"Curr Med Sci"},{"key":"10.1016\/j.gendis.2025.101991_bib165","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.632364","article-title":"Inhibition of LDH-a by oxamate enhances the efficacy of anti-PD-1 treatment in an NSCLC humanized mouse model","volume":"11","author":"Qiao","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib166","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.3390\/molecules28062509","article-title":"Design, synthesis and biological evaluation of quinoline-8-sulfonamides as inhibitors of the tumor cell-specific M2 isoform of pyruvate kinase: preliminary study","volume":"28","author":"Marciniec","year":"2023","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib167","doi-asserted-by":"crossref","DOI":"10.1016\/j.yexcr.2020.112282","article-title":"Prognostic and therapeutic relevance of phosphofructokinase platelet-type (PFKP) in breast cancer","volume":"396","author":"Umar","year":"2020","journal-title":"Exp Cell Res"},{"key":"10.1016\/j.gendis.2025.101991_bib168","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.1034397","article-title":"Combining metformin with lactate transport inhibitors as a treatment modality for cancer - recommendation proposal","volume":"12","author":"Benjamin","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib169","doi-asserted-by":"crossref","first-page":"135","DOI":"10.37349\/etat.2024.00210","article-title":"Exploring monocarboxylate transporter inhibition for cancer treatment","volume":"5","author":"Koltai","year":"2024","journal-title":"Explor Target Antitumor Ther"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib170","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1038\/s41416-019-0717-x","article-title":"Monocarboxylate transporter 1 blockade with AZD3965 inhibits lipid biosynthesis and increases tumour immune cell infiltration","volume":"122","author":"Beloueche-Babari","year":"2020","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib171","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/hep.32348","article-title":"Monocarboxylate transporter 4 inhibition potentiates hepatocellular carcinoma immunotherapy through enhancing T cell infiltration and immune attack","volume":"77","author":"Fang","year":"2023","journal-title":"Hepatology"},{"issue":"16_suppl","key":"10.1016\/j.gendis.2025.101991_bib172","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1200\/JCO.2023.41.16_suppl.3099","article-title":"Phase 1 results of CYT-0851, a monocarboxylate transporter (MCT) inhibitor, in combination with capecitabine (cape) or gemcitabine (gem) in advanced solid tumors","volume":"41","author":"Lynch","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib173","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1208\/s12248-018-0261-2","article-title":"In vitro and in vivo efficacy of the monocarboxylate transporter 1 inhibitor AR-C155858 in the murine 4T1 breast cancer tumor model","volume":"21","author":"Guan","year":"2018","journal-title":"AAPS J"},{"issue":"22 Pt 1","key":"10.1016\/j.gendis.2025.101991_bib174","doi-asserted-by":"crossref","first-page":"6689","DOI":"10.1158\/1078-0432.CCR-07-1477","article-title":"Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma","volume":"13","author":"Ebbinghaus","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"17","key":"10.1016\/j.gendis.2025.101991_bib175","doi-asserted-by":"crossref","first-page":"9438","DOI":"10.3390\/ijms25179438","article-title":"Targeting CD36-mediated lipid metabolism by selective inhibitor-augmented antitumor immune responses in oral cancer","volume":"25","author":"Takaichi","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"12","key":"10.1016\/j.gendis.2025.101991_bib176","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.3390\/cells12121605","article-title":"The role of CD36 in cancer progression and its value as a therapeutic target","volume":"12","author":"Feng","year":"2023","journal-title":"Cells"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib177","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.canlet.2014.03.015","article-title":"Inactivation of ATP citrate lyase by cucurbitacin B: a bioactive compound from cucumber, inhibits prostate cancer growth","volume":"349","author":"Gao","year":"2014","journal-title":"Cancer Lett"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib178","doi-asserted-by":"crossref","first-page":"32","DOI":"10.3892\/or.2022.8469","article-title":"Combined inhibition of ACLY and CDK4\/6 reduces cancer cell growth and invasion","volume":"49","author":"Velez","year":"2023","journal-title":"Oncol Rep"},{"key":"10.1016\/j.gendis.2025.101991_bib179","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117510","article-title":"Morusin, a novel inhibitor of ACLY, induces mitochondrial apoptosis in hepatocellular carcinoma cells through ROS-mediated mitophagy","volume":"180","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"15","key":"10.1016\/j.gendis.2025.101991_bib180","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.7150\/jca.26374","article-title":"TOFA induces cell cycle arrest and apoptosis in ACHN and 786-O cells through inhibiting PI3K\/Akt\/mTOR pathway","volume":"9","author":"He","year":"2018","journal-title":"J Cancer"},{"key":"10.1016\/j.gendis.2025.101991_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2019.105010","article-title":"Synthesis and anti-cancer activity of ND-646 and its derivatives as acetyl-CoA carboxylase 1 inhibitors","volume":"137","author":"Li","year":"2019","journal-title":"Eur J Pharmaceut Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib182","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.cmet.2018.08.020","article-title":"Inhibition of acetyl-CoA carboxylase by phosphorylation or the inhibitor ND-654 suppresses lipogenesis and hepatocellular carcinoma","volume":"29","author":"Lally","year":"2019","journal-title":"Cell Metab"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib183","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.urolonc.2011.01.003","article-title":"Metformin inhibits renal cell carcinoma in vitro and in vivo xenograft","volume":"31","author":"Liu","year":"2013","journal-title":"Urol Oncol"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib184","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s12032-025-02697-2","article-title":"Fatty acid synthase inhibitor cerulenin attenuates glioblastoma progression by reducing EMT and stemness phenotypes, inducing oxidative and ER stress response, and targeting PI3K\/AKT\/NF-\u03baB axis","volume":"42","author":"Pekmez","year":"2025","journal-title":"Med Oncol"},{"key":"10.1016\/j.gendis.2025.101991_bib185","series-title":"Targeting Fatty Acid Synthase Suppresses Tumor Development in NF2\/CDKN2A-deficient Malignant Pleural Mesothelioma","author":"Karnan","year":"2026171287"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib186","doi-asserted-by":"crossref","DOI":"10.1016\/j.jlr.2024.100660","article-title":"Fatty acid synthase inhibitor cerulenin hinders liver cancer stem cell properties through FASN\/APP axis as novel therapeutic strategies","volume":"65","author":"Chen","year":"2024","journal-title":"J Lipid Res"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib187","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.juro.2008.03.186","article-title":"Pharmacological inhibitor of fatty acid synthase suppresses growth and invasiveness of renal cancer cells","volume":"180","author":"Horiguchi","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.gendis.2025.101991_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113426","article-title":"Low-dose orlistat promotes the therapeutic effect of oxaliplatin in colorectal cancer","volume":"153","author":"Zhang","year":"2022","journal-title":"Biomed Pharmacother"},{"issue":"6","key":"10.1016\/j.gendis.2025.101991_bib189","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1007\/s11684-020-0804-7","article-title":"Orlistat induces ferroptosis-like cell death of lung cancer cells","volume":"15","author":"Zhou","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.gendis.2025.101991_bib190","doi-asserted-by":"crossref","DOI":"10.1016\/j.taap.2020.114918","article-title":"Orlistat delays hepatocarcinogenesis in mice with hepatic co-activation of AKT and c-Met","volume":"392","author":"Zhang","year":"2020","journal-title":"Toxicol Appl Pharmacol"},{"key":"10.1016\/j.gendis.2025.101991_bib191","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.100797","article-title":"First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors","volume":"34","author":"Falchook","year":"2021","journal-title":"EClinicalMedicine"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib192","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1186\/s12935-024-03611-y","article-title":"Protein kinase CK2 sustains de novo fatty acid synthesis by regulating the expression of SCD-1 in human renal cancer cells","volume":"24","author":"Guerra","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"14","key":"10.1016\/j.gendis.2025.101991_bib193","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.1016\/j.bmc.2017.05.016","article-title":"Discovery of novel and potent stearoyl coenzyme a desaturase 1 (SCD1) inhibitors as anticancer agents","volume":"25","author":"Imamura","year":"2017","journal-title":"Bioorg Med Chem"},{"issue":"9","key":"10.1016\/j.gendis.2025.101991_bib194","doi-asserted-by":"crossref","first-page":"4570","DOI":"10.3390\/ijms22094570","article-title":"Functions of thrombospondin-1 in the tumor microenvironment","volume":"22","author":"Kaur","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10.1016\/j.gendis.2025.101991_bib195","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/cam4.65","article-title":"A phase I study of ABT-510 plus bevacizumab in advanced solid tumors","volume":"2","author":"Uronis","year":"2013","journal-title":"Cancer Med"},{"key":"10.1016\/j.gendis.2025.101991_bib196","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.2147\/DDDT.S251865","article-title":"Bempedoic acid for heterozygous familial hypercholesterolemia: from bench to bedside","volume":"15","author":"Agarwala","year":"2021","journal-title":"Drug Des Dev Ther"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib197","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1080\/07853890.2022.2059559","article-title":"Bempedoic acid and its role in contemporary management of hyperlipidemia in atherosclerosis","volume":"54","author":"Tummala","year":"2022","journal-title":"Ann Med"},{"issue":"17","key":"10.1016\/j.gendis.2025.101991_bib198","doi-asserted-by":"crossref","first-page":"8180","DOI":"10.1158\/0008-5472.CAN-07-0389","article-title":"Chemical inhibition of acetyl-CoA carboxylase induces growth arrest and cytotoxicity selectively in cancer cells","volume":"67","author":"Beckers","year":"2007","journal-title":"Cancer Res"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib199","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1002\/jcp.25598","article-title":"Nephroprotective effects of metformin in diabetic nephropathy","volume":"232","author":"Ravindran","year":"2017","journal-title":"J Cell Physiol"},{"key":"10.1016\/j.gendis.2025.101991_bib200","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ctrv.2017.01.005","article-title":"Combination of metformin with chemotherapeutic drugs via different molecular mechanisms","volume":"54","author":"Peng","year":"2017","journal-title":"Cancer Treat Rev"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib201","doi-asserted-by":"crossref","first-page":"248","DOI":"10.2741\/4484","article-title":"Metformin suppresses CRC growth by inducing apoptosis via ADORA1","volume":"22","author":"Lan","year":"2017","journal-title":"Front Biosci (Landmark Ed)"},{"key":"10.1016\/j.gendis.2025.101991_bib202","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111454","article-title":"Mechanism and application of metformin in kidney diseases: an update","volume":"138","author":"Song","year":"2021","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib203","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1016\/j.clgc.2016.04.012","article-title":"Metformin use and outcome of sunitinib treatment in patients with diabetes and metastatic renal cell carcinoma","volume":"14","author":"Keizman","year":"2016","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib204","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.clgc.2016.06.017","article-title":"Effect of metformin use on survival outcomes in patients with metastatic renal cell carcinoma","volume":"15","author":"Hamieh","year":"2017","journal-title":"Clin Genitourin Cancer"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib205","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11523-022-00907-9","article-title":"Concomitant use of statins, metformin, or proton pump inhibitors in patients with advanced renal cell carcinoma treated with first-line combination therapies","volume":"17","author":"Santoni","year":"2022","journal-title":"Target Oncol"},{"issue":"5475","key":"10.1016\/j.gendis.2025.101991_bib206","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1126\/science.288.5475.2379","article-title":"Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors","volume":"288","author":"Loftus","year":"2000","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib207","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1038\/s42255-021-00479-4","article-title":"Pharmacological inhibition of fatty acid synthesis blocks SARS-CoV-2 replication","volume":"3","author":"Chu","year":"2021","journal-title":"Nat Metab"},{"key":"10.1016\/j.gendis.2025.101991_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175456","article-title":"Potential of Orlistat to induce apoptotic and antiangiogenic effects as well as inhibition of fatty acid synthesis in breast cancer cells","volume":"939","author":"Jovanki\u0107","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"36","key":"10.1016\/j.gendis.2025.101991_bib209","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000034671","article-title":"Pharmacological effect and mechanism of orlistat in anti-tumor therapy: a review","volume":"102","author":"Hao","year":"2023","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib210","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40170-025-00375-5","article-title":"CD36 inhibition enhances the anti-proliferative effects of PI3K inhibitors in PTEN-loss anti-HER2 resistant breast cancer cells","volume":"13","author":"Liu","year":"2025","journal-title":"Cancer Metab"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib211","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s11306-024-02179-y","article-title":"Combination of low glucose and SCD1 inhibition impairs cancer metabolic plasticity and growth in MCF-7 cancer cells: a comprehensive metabolomic and lipidomic analysis","volume":"20","author":"Zhu","year":"2024","journal-title":"Metabolomics"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib212","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1186\/s12935-024-03540-w","article-title":"Stearoyl CoA desaturase inhibition can effectively induce apoptosis in bladder cancer stem cells","volume":"24","author":"Li","year":"2024","journal-title":"Cancer Cell Int"},{"issue":"7","key":"10.1016\/j.gendis.2025.101991_bib213","doi-asserted-by":"crossref","first-page":"948","DOI":"10.3390\/cancers11070948","article-title":"Stearoyl-CoA desaturase 1 as a therapeutic target for the treatment of cancer","volume":"11","author":"Tracz-Gaszewska","year":"2019","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.gendis.2025.101991_bib214","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1038\/s41375-024-02390-9","article-title":"Stearoyl-CoA desaturase inhibition is toxic to acute myeloid leukemia displaying high levels of the de novo fatty acid biosynthesis and desaturation","volume":"38","author":"Dembitz","year":"2024","journal-title":"Leukemia"},{"key":"10.1016\/j.gendis.2025.101991_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.phymed.2022.154102","article-title":"Agrimonolide inhibits cancer progression and induces ferroptosis and apoptosis by targeting SCD1 in ovarian cancer cells","volume":"101","author":"Liu","year":"2022","journal-title":"Phytomedicine"},{"issue":"10","key":"10.1016\/j.gendis.2025.101991_bib216","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1038\/s41591-021-01495-3","article-title":"Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial","volume":"27","author":"Ratziu","year":"2021","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.gendis.2025.101991_bib217","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3390\/ijms26031186","article-title":"Lipids metabolism inhibition antiproliferative synergy with 5-fluorouracil in human colorectal cancer model","volume":"26","author":"Zabielska","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib218","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/j.molcel.2024.12.025","article-title":"OXCT1 succinylation and activation by SUCLA2 promotes ketolysis and liver tumor growth","volume":"85","author":"Guo","year":"2025","journal-title":"Mol Cell"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib219","first-page":"1499","article-title":"An anti-ASCT2 monoclonal antibody suppresses gastric cancer growth by inducing oxidative stress and antibody dependent cellular toxicity in preclinical models","volume":"8","author":"Osanai-Sasakawa","year":"2018","journal-title":"Am J Cancer Res"},{"issue":"15","key":"10.1016\/j.gendis.2025.101991_bib220","doi-asserted-by":"crossref","first-page":"3248","DOI":"10.1158\/1078-0432.CCR-22-0061","article-title":"Telaglenastat plus everolimus in advanced renal cell carcinoma: a randomized, double-blinded, placebo-controlled, phase II ENTRATA trial","volume":"28","author":"Lee","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"Suppl 1","key":"10.1016\/j.gendis.2025.101991_bib221","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1186\/s12885-023-10971-7","article-title":"A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679\/ECHO-302)","volume":"23","author":"Lara","year":"2024","journal-title":"BMC Cancer"},{"issue":"19","key":"10.1016\/j.gendis.2025.101991_bib222","doi-asserted-by":"crossref","DOI":"10.1172\/JCI157649","article-title":"TDO2+ myofibroblasts mediate immune suppression in malignant transformation of squamous cell carcinoma","volume":"132","author":"Hu","year":"2022","journal-title":"J Clin Invest"},{"issue":"2","key":"10.1016\/j.gendis.2025.101991_bib223","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000870","article-title":"Preclinical investigations and a first-in-human phase I trial of M4112, the first dual inhibitor of indoleamine 2, 3-dioxygenase 1 and tryptophan 2, 3-dioxygenase 2, in patients with advanced solid tumors","volume":"8","author":"Naing","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.gendis.2025.101991_bib224","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s00280-020-04218-6","article-title":"The role of the glutamine transporter ASCT2 in antineoplastic therapy","volume":"87","author":"Teixeira","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"issue":"18","key":"10.1016\/j.gendis.2025.101991_bib225","doi-asserted-by":"crossref","first-page":"4994","DOI":"10.1158\/1078-0432.CCR-21-1204","article-title":"A phase I dose-escalation and expansion study of telaglenastat in patients with advanced or metastatic solid tumors","volume":"27","author":"Harding","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib226","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-21-2972","article-title":"Telaglenastat plus cabozantinib or everolimus for advanced or metastatic renal cell carcinoma: an open-label phase I trial","volume":"28","author":"Meric-Bernstam","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"5","key":"10.1016\/j.gendis.2025.101991_bib227","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2025.104536","article-title":"A phase I\/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer","volume":"10","author":"Gouda","year":"2025","journal-title":"ESMO Open"},{"key":"10.1016\/j.gendis.2025.101991_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102461","article-title":"Indoleamine 2, 3-dioxygenase (IDO) inhibitors and cancer immunotherapy","volume":"110","author":"Fujiwara","year":"2022","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.gendis.2025.101991_bib229","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1134551","article-title":"The catalytic inhibitor epacadostat can affect the non-enzymatic function of IDO1","volume":"14","author":"Panfili","year":"2023","journal-title":"Front Immunol"},{"issue":"13","key":"10.1016\/j.gendis.2025.101991_bib230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241310668","article-title":"Unlocking the potential of arginine deprivation therapy: recent breakthroughs and promising future for cancer treatment","volume":"24","author":"Chu","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.gendis.2025.101991_bib231","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1186\/s12964-025-02328-3","article-title":"Urea cycle dysregulation: a new frontier in cancer metabolism and immune evasion","volume":"23","author":"Shou","year":"2025","journal-title":"Cell Commun Signal"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib232","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1097\/JS9.0000000000001479","article-title":"Comparative investigation of neoadjuvant immunotherapy versus adjuvant immunotherapy in perioperative patients with cancer: a global-scale, cross-sectional, and large-sample informatics study","volume":"110","author":"Guo","year":"2024","journal-title":"Int J Surg"},{"issue":"8","key":"10.1016\/j.gendis.2025.101991_bib233","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-011040","article-title":"Immune-related adverse events of neoadjuvant immunotherapy in patients with perioperative cancer: a machine-learning-driven, decade-long informatics investigation","volume":"13","author":"Guo","year":"2025","journal-title":"J Immunother Cancer"},{"issue":"20","key":"10.1016\/j.gendis.2025.101991_bib234","doi-asserted-by":"crossref","first-page":"5701","DOI":"10.1016\/j.cell.2025.06.027","article-title":"Glucose restriction shapes pre-metastatic innate immune landscapes in the lung through exosomal TRAIL","volume":"188","author":"Wu","year":"2025","journal-title":"Cell"}],"container-title":["Genes &amp; Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004805?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352304225004805?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:45:47Z","timestamp":1790012747000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352304225004805"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":234,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S2352304225004805"],"URL":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101991","relation":{},"ISSN":["2352-3042"],"issn-type":[{"value":"2352-3042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Research progress in metabolic reprogramming and targeting metabolic pathways for clear cell renal cell carcinoma","name":"articletitle","label":"Article Title"},{"value":"Genes & Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.gendis.2025.101991","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Publishing services by Elsevier B.V. on behalf of KeAi Communications Co. Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101991"}}